A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Toshiro ShirakawaAkinobu Gotoh

Abstract

Cyclooxygenase-2 (Cox-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. In the present study, we examined the feasibility of using Cox-2 promoter-based replication-selective adenovirus for targeting bladder cancer cells that express Cox-2 transcriptional activity. A series of human cancer cell lines, including three bladder cancer cell lines (KK47, T24, and 5637), were evaluated for their Cox-2 and CAR (the Coxsackievirus and adenovirus receptor) mRNA expression levels by quantitative real-time PCR. AdE3-cox2-327, a replication-selective adenovirus in which the expression of E1a is controlled by the Cox-2 promoter, was generated, and its tissue-specific activity was tested in vitro and in vivo. Three bladder cancer cell lines express higher levels of Cox-2 mRNA than does the human prostate cancer cell line PC3, the primary cultured human benign prostatic fibroblast, PF cells, and the human colon cancer cell line Colo320. Relatively higher expression of CAR mRNA was detected in the KK47, 5637, respectively, and Colo320 than in the T24, PC-3, and PF cells. In vitro assays revealed significant growth suppression of...Continue Reading

References

Nov 5, 1985·Biochemistry·P BeimlingK Moelling
Mar 1, 1987·The Journal of General Virology·F L Graham
May 1, 1973·International Journal of Cancer. Journal International Du Cancer·J BubeníkJ Donner
Nov 1, 1973·Journal of the National Cancer Institute·D J GiardW P Parks
Apr 1, 1973·Virology·F L Graham, A J van der Eb
Sep 13, 1994·Proceedings of the National Academy of Sciences of the United States of America·A J BettF L Graham
May 1, 1994·European Journal of Biochemistry·T KosakaT Tanabe
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·R P TomkoL Philipson
Feb 12, 1998·Proceedings of the Society for Experimental Biology and Medicine·K SubbaramaiahA J Dannenberg
Nov 13, 1998·Science·M C CoffeyP W Lee
Jul 6, 2000·The American Journal of Pathology·M KömhoffM D Breyer
Mar 15, 2002·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Carola BiedererFrank McCormick

❮ Previous
Next ❯

Citations

Mar 26, 2011·Cancer Gene Therapy·R M Eager, J Nemunaitis
Nov 26, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·John NemunaitisToshiyoshi Fujiwara
Feb 13, 2007·Urologia Internationalis·Maurizio BuscariniBernard Bochner
Jan 14, 2005·Proceedings of the National Academy of Sciences of the United States of America·Zhao-Zhong SuPaul B Fisher
Jan 18, 2006·Reviews in Medical Virology·Adam M SonabendMaciej S Lesniak
Feb 21, 2006·Biochemical and Biophysical Research Communications·Fumiaki SatoStephen J Meltzer
Jul 14, 2017·Virus Genes·Julia Niemann, Florian Kühnel
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Justyna LejaMagnus Essand
Apr 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eduardo G CafferataOsvaldo L Podhajcer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.